ACM
BIOA

ADAR1 Capital Management’s BioAge Labs BIOA Stock Holding History

ADAR1 Capital Management’s Portfolio BIOA Stock Details BIOA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-135,560
Closed -$2.37M – 352
2026
Q1 		$2.37M Hold
135,560
– – 0.14% 117
2025
Q4 		$1.79M Sell
135,560
-1,744,513
-93% -$15.5M 0.13% 106
2025
Q3 		$11.1M Sell
1,880,073
-57,050
-3% -$267K 1.04% 21
2025
Q2 		$8M Buy
1,937,123
+966,023
+99% +$3.89M 1.23% 21
2025
Q1 		$3.65M Buy
971,100
+848,063
+689% +$3.92M 0.68% 43
2024
Q4 		$712K Buy
+123,037
New +$2.12M 0.14% 95

Other funds holding BIOA

ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

ADAR1 Capital Management's BIOA Position: Q2 2026 in Review

ADAR1 Capital Management sold out of BioAge Labs (BIOA) in Q2 2026, closing a stake of 135,560 shares — an estimated $2.37M sold.

ADAR1 Capital Management first reported a position in BIOA in Q4 2024 and held it in 6 quarters. The position peaked at $11.1M in Q3 2025. 151 funds tracked by Wall St. Rank hold BIOA as of Q2 2026.

  • ADAR1 Capital Management reported no remaining BioAge Labs position as of Q2 2026 after selling out during the quarter.
  • ADAR1 Capital Management sold 135,560 BioAge Labs shares in Q2 2026, an estimated $2.37M.
  • ADAR1 Capital Management first reported a position in BioAge Labs in Q4 2024 and held it in 6 quarters.
  • ADAR1 Capital Management's BioAge Labs position peaked at $11.1M in Q3 2025.
  • 151 funds tracked by Wall St. Rank held BioAge Labs as of Q2 2026.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.